The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Cagrilintide's dosing interval and the pharmacokinetics behind it

This is a generated summary. It shows the 9 most-liked posts from a topic of 106, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
RM
r.mwangiTL2 Moderator Solution30 Sep 2025#5
l.chevalier, post #2: Picking up the opening post: that is the part I would want checked first. For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use. Go to post

Two things before anyone answers the substance.

First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.

30 likes in reply to #2 10mo
JD
j.delacroixTL3Regular1 Oct 2025#16

I read post #14 twice before replying, because I had assumed the opposite.

Nausea profile of amylin analogues: the historical agent pramlintide required multiple daily doses and had a difficult tolerability profile. A weekly formulation is a substantially different proposition and data from that is more relevant than data from pramlintide.

31 likes 10mo
FL
f.lindholmTL2 Moderator1 Oct 2025#23

On post #19 — agreed on the reasoning, with one qualification.

The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.

29 likes 10mo
PL
p.lindqvistTL2 Moderator3 Oct 2025#48

Picking up post #45: that is the part I would want checked first.

Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.

31 likes 10mo
F
FFaulknerTL3Regular3 Oct 2025#56

Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years.

33 likes 10mo
PP
peak_purityTL3Analytical chemist4 Oct 2025#68

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.

26 likes 10mo
JH
j.hartmannTL2 Moderator4 Oct 2025#76

Worth separating two things that post #72 runs together.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

28 likes 10mo
DB
d.barrosTL2 Moderator5 Oct 2025#97

Gastric emptying: both amylin and GLP-1 slow it, through partly overlapping but distinct mechanisms. Whether the slowing at a higher magnitude produces disproportionate nausea or is tolerable is a question phase 3 exists to answer.

28 likes 10mo
AS
a.stephanopoulosTL3Regular6 Oct 2025#106
m.malinowski, post #11: What is genuinely unknown about long-term amylin agonism: real-world response rates, whether effect is durable with continued use, whether satiety adaptation occurs over months or years, safety profile in populations not enrolled in the trials. Go to post

I read post #104 twice before replying, because I had assumed the opposite.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

32 likes in reply to #11 10mo

Read the full topic (106 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1
On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I…
IDNMTNAFMB+27 31 671 12mo
Amylin and gastric emptying: overlapping mechanisms with incretins
On the subject in the title: Amylin and gastric emptying: overlapping mechanisms with incretins Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting;…
TNLKA 2 50k 17mo
Cagrilintide molecular characteristics and analytical considerations
Cagrilintide molecular characteristics and analytical considerations — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in support of a claim I…
KDPOARNSJH 4 41k 12mo
Reading a combination trial: attributing effect to components
On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it before…
VMAHTTSVP 4 19k 11mo
Follow-up: Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…
CLBKSS 2 41k 14mo

Related topics — sharing the tags effect size, randomised trial, amylin analogues

TopicParticipantsRepliesViewsActivity
Retatrutide dose escalation in the published trials
Posting this under the heading it deserves: Retatrutide dose escalation in the published trials Everything below is what sits behind that. Session topic: SURPASS-2 ( N Engl J Med , 2021). Please read it…
RMCCYMRMJW+149 159 30k 15mo
Coming back to: Measurement error in a self-reported exposure
Measurement error in a self-reported exposure — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
LARNOAKACD+23 27 49k 3mo
Coming back to: A critique that turned out to be unfair, retracted by its author
A critique that turned out to be unfair, retracted by its author — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not…
IAQLJB 2 1.3k 14mo
Journal club: SUSTAIN 6 and its retinopathy signal
On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I do not think it…
LAMRZHOJI+110 122 46k 1d
Open-label extensions: what survives and what does not
Posting this under the heading it deserves: Open-label extensions: what survives and what does not Everything below is what sits behind that. Comparing STEP 8 ( JAMA , 2022) with PIONEER 6 ( N Engl J Med ,…
PQZILUCMB 4 22k 3mo